NYSE · Healthcare · Statistics
Abbott Laboratories (ABT) Valuation & Key Statistics
Valuation, profitability, balance-sheet health, and risk metrics for ABT, refreshed each market session.
Section freshness
Prices as of Sep 8, 12:24 PM EDT · Fundamentals checked Sep 8, 12:24 PM EDT · Statements Mar 31, 2026
Key metrics at a glance
The numbers most investors check first
Market cap
$183.37B
P/E (TTM)
34.29
Forward P/E
—
FCF yield
4.02%
Return on equity
12.06%
Dividend yield
2.33%
Valuation
- Market cap
- $183.37B
- Enterprise value
- $210.61B
- P/E (TTM)
- 34.29
- Price / sales
- 4.06
- Price / book
- 3.52
- EPS (TTM)
- $3.09
Long-run compounding
20-year CAGR and aggregate price growth.
Adjusted daily closes are annualized over the tracked 20-year window; dividends are not included in this price-only return view.
- 20Y CAGR
- 10.45%
- From earliest tracked adjusted close on September 8, 2006
- Aggregate CAGR
- -0.38%
- 1Y, 3Y, 5Y, 10Y blended CAGR
- First tracked close
- $14.85
- September 8, 2006
- History span
- 20 yrs
- Sep 8, 2006 to Sep 4, 2026 · 5,029 closes
- Latest tracked close
- $108.33
- September 4, 2026
- 20Y high
- $142.60
- December 27, 2021
- 20Y low
- $19.80
- May 1, 2009
- History source
- Long range
- Yahoo Finance
Valuation map
Risk and scale
Less volatile than the market
Pro formula stack
Ratios investors search for after the headline quote.
These are TECHi-computed from overview, income statement, balance sheet, and cash-flow rows when market-data sources expose the ingredients.
- EV / revenue
- 4.67
- Enterprise value / TTM revenue
- FCF yield
- 4.02%
- TTM free cash flow / market cap
- FCF / share
- $4.24
- TTM free cash flow / shares outstanding
- Earnings yield
- 2.92%
- Inverse P/E
- Rule of 40
- 24.13%
- Revenue growth + FCF margin
- ROIC approx.
- 7.49%
- NOPAT / invested capital
- CROIC
- 9.30%
- FCF / invested capital
- TECHi quality score
- 5 / 7
- 7-point profitability, cash, leverage, and trend check
Quality and capital returns
TTM free cash flow / TTM revenue
TTM FCF / TTM net income
TTM revenue / market cap
Balance-sheet and reinvestment reads
Total debt / TTM FCF
Tech-stock reinvestment intensity
Capital intensity of the business
Distress and optionality read
ABT Altman Z-score needs a fuller balance sheet.
TECHi computes a non-financial-company Altman-style score from working capital, retained earnings, EBIT, market value, liabilities, revenue, and assets. It is not a bankruptcy prediction, but it gives pro readers a fast stress screen that most quote pages do not show beside live valuation metrics.
- Net cash / share
- $-15.64
- Cash minus debt, per share
- Working capital
- $7.13B
- Current assets minus current liabilities
- Debt growth YoY
- +157.11%
- Latest quarter vs same quarter last year
Valuation read
ABT trades at 34.29× trailing earnings.
A trailing P/E above 30 means the market is paying up for ABT. That premium has to be earned with above-average revenue or earnings growth.
Profitability
- Gross margin
- 37.08%
- Operating margin
- 17.07%
- Net margin
- 13.91%
- Return on equity
- 12.06%
- Return on assets
- 5.68%
- Debt / equity
- 0.65
- Current ratio
- 1.39
- >1 = covers near-term liabilities
- Beta (5Y)
- 0.59
Margin profile
Profitability read
ABT converts 13.9% of revenue into net income.
Margins in the high single-digits to high-teens are the bulk of the index. The differentiated reads here are operating-margin direction (improving = leverage) and ROE — the latter tells you how much equity capital management actually needs.
Per-share & range
- Dividend yield
- 2.33%
- Forward yield
- Payout ratio
- 20.39%
- Dividend per share / EPS — lower leaves more room to grow
- Dividend coverage
- 6.72×
- TTM free cash flow / dividends paid — above 1× is self-funded
- Shares outstanding
- 1.74B
- 52w high
- $137.49
- 52w low
- $81.97
Corporate actions
Stock split history
Adjusted for all historical splits
- Split events
- 0
Reported fundamentals
Company statistics fields
These figures come from the latest issuer filings and live quote-derived formulas.
- Revenue (TTM)
- $45.13B
- TECHi unified data
- Book value
- $29.89
- TECHi unified data
- Revenue / share
- $25.91
- TECHi unified data
- Earnings growth YoY
- -19.74%
- TECHi unified data
- Revenue growth YoY
- 7.78%
- TECHi unified data
- 50-day average
- $104.21
- TECHi unified data
- 200-day average
- $105.22
- TECHi unified data
- Dividend / share
- $0.63
- Yahoo Finance
- Ex-dividend date
- July 15, 2026
- Yahoo Finance
Frequently asked
Common questions.
What is Abbott Laboratories's market capitalization?
Abbott Laboratories (ABT) has a market capitalization of $183.4 billion.
What is ABT's P/E ratio?
ABT trades at a trailing price-to-earnings ratio of 34.29.
Where do TECHi's ABT statistics come from?
ABT statistics combine exchange quotes with company filings through TECHi's market-data providers. Any figure that is missing or out of date is left blank rather than estimated.